CHRONIC DIPHENYLHYDANTOIN THERAPY DOES NOT REDUCE PLASMA 25-HYDROXY-VITAMIN-D

被引：26

作者：

WARK, JD

LARKINS, RG

PERRYKEENE, D

PETER, CT

ROSS, DL

SLOMAN, JG

机构：

[1] ROYAL MELBOURNE HOSP,DEPT ENDOCRINOL,MELBOURNE 3050,VICTORIA,AUSTRALIA

[2] ROYAL MELBOURNE HOSP,DEPT CARDIOL,MELBOURNE 3050,VICTORIA,AUSTRALIA

来源：

CLINICAL ENDOCRINOLOGY | 1979年 / 11卷 / 03期

关键词：

D O I：

10.1111/j.1365-2265.1979.tb03074.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A randomized controlled study was performed to investigate the effect of 2 years’monitored diphenylhydantoin (DPH) therapy on plasma 25‐hydroxyvitamin D (25‐OHD) in nonepileptic, non‐institutionalized subjects. Mean ± SEM plasma 25‐OHD of 18 DPH‐treated subjects at the end of 2 years’drug treatment was 59 ± 8 nmol/l (23.6 ± 3.2 ng/ml), which was not decreased compared to that of eighteen control subjects (54±8 nmol/l, 21.6±3.2 ng/ml). In addition, mean plasma 25‐OHD had not changed 1 month after ceasing DPH. The treated group had a higher mean serum alkaline phosphatase (SAP) during DPH treatment, attributable to hepatic enzyme induction. It is concluded that therapeutic doses of DPH without other anticonvulsants do not have a clinically significant effect on plasma 25‐OHD. Copyright © 1979, Wiley Blackwell. All rights reserved

引用

页码：267 / 274

页数：8

共 26 条

[1] RELATIONSHIP BETWEEN PLASMA LEVEL OF DIPHENYLHYDANTOIN SODIUM AND ITS CARDIAC ANTIARRHYTHMIC EFFECTS [J].